Midatech Pharma PlcのRPE

Midatech Pharma PlcのRPEは何ですか。

Midatech Pharma PlcのRPEは29.444k£です。

RPEの定義は何ですか。

従業員1人当たりの収益(RPE)は、収益を組織の従業員の数で割ったものです。

LSEのセクタHealth CareにおけるRPEの企業と比べるMidatech Pharma Plc

Midatech Pharma Plcは何をしますか。

Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Midatech Pharma Plcと類似のrpe